Kamada Ltd. (KMDA) Downgraded to Sell at Zacks Investment Research
According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “
Several other research analysts have also recently issued reports on the stock. TheStreet upgraded shares of Kamada from a sell rating to a hold rating in a report on Monday, September 26th. Jefferies Group restated a buy rating and issued a $7.00 target price on shares of Kamada in a report on Wednesday, August 31st. Finally, HC Wainwright restated a buy rating and issued a $10.00 target price on shares of Kamada in a report on Saturday, September 3rd.
Shares of Kamada (NASDAQ:KMDA) traded up 5.30% during mid-day trading on Wednesday, reaching $5.37. 92,659 shares of the company’s stock traded hands. The company’s market cap is $195.56 million. Kamada has a 12-month low of $3.26 and a 12-month high of $5.45. The firm has a 50-day moving average of $4.78 and a 200 day moving average of $4.09.
Kamada (NASDAQ:KMDA) last announced its earnings results on Tuesday, August 2nd. The company reported ($0.04) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.04). The business had revenue of $19.10 million for the quarter, compared to the consensus estimate of $18.50 million. Kamada had a negative net margin of 9.92% and a negative return on equity of 10.59%. Equities analysts forecast that Kamada will post ($0.19) EPS for the current year.
A number of institutional investors have recently made changes to their positions in the stock. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Kamada during the second quarter valued at approximately $1,701,000. Vanguard Group Inc. raised its position in shares of Kamada by 19.0% in the second quarter. Vanguard Group Inc. now owns 327,533 shares of the company’s stock valued at $1,202,000 after buying an additional 52,195 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Kamada by 2.4% in the first quarter. Renaissance Technologies LLC now owns 170,300 shares of the company’s stock valued at $652,000 after buying an additional 4,000 shares in the last quarter. 5.31% of the stock is owned by institutional investors and hedge funds.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.